Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Marta Alonso Fernández de Gatta, MD PhD, Ana Martín García, MD PhD, Félix López Cadenas, MD, Díaz Peláez Elena, MD, Tamara Jimenez, Jesus Maria . Hernández-Rivas, MD, Victor Vallejo García, MD, Manuel Barreiro Pérez, MD, Lucia Rodríguez Estévez, MD, Juan Carlos Castro Garay, Diego Ávila, MD, Adolfo Alejandro Cabanillas Cabral, MD, Clara Sánchez Pablo, MD, María Díez-Campelo, MD PhD, Pedro Luís Sánchez Fernández, MD PhD

Blood (2019) 134 (Supplement_1): 1727.

https://doi.org/10.1182/blood-2019-127938

Published: 2019

Journal Articles

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Ujjawal H Gandhi, PhDMBBS, Hanna Von Haefen, Robert Hoffman, MD PhD, Alexandra Ritts, MD, Sharon Phillips, MSPH, Oluchi Ukaegbu, MD, Samuel Rubinstein, MD, Shelton Lacy Harrell, MSN, Stacey A. Goodman, MD MS, Daniel Lenihan, MD, David Slosky, MD, Rebecca Hung, MD PhD, Robert Frank Cornell, MD

Blood (2017) 130 (Supplement 1): 1881.

https://doi.org/10.1182/blood.V130.Suppl_1.1881.1881

Published: 2017

Journal Articles

Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin

Blood (2017) 130 (Supplement 1): 3901.

https://doi.org/10.1182/blood.V130.Suppl_1.3901.3901

Published: 2017

Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD

Blood (2016) 128 (22): 2032.

https://doi.org/10.1182/blood.V128.22.2032.2032

Published: 2016

Journal Articles

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Manuel Ayala, MD, Jacqueline Domínguez, NL, Iván Bonilla, MD

Blood (2016) 128 (22): 5430.

https://doi.org/10.1182/blood.V128.22.5430.5430

Published: 2016

Journal Articles

Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568

Kai Xue, MD, Juan J Gu, PhD, Qunling Zhang, MD, Xiaojian Liu, MD, Jiachen Wang, Jianfeng Luo, Francisco J. Hernandez-Ilizaliturri, MD, Stanley F. Fernandez, MD, Myron S. Czuczman, MD, Junning Cao, MD Associate Professor, Xiaonan Hong, MD, Ye Guo, MD

Blood (2014) 124 (21): 3041.

https://doi.org/10.1182/blood.V124.21.3041.3041

Published: 2014

Journal Articles

Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center

Zandra K. Klippel, MD, Barry Storer, PhD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Pamela S Becker, MD, PhD, Damian J. Green, MD, Nicholas Burwick, MD, Edward N. Libby, III, MD

Blood (2012) 120 (21): 2016.

https://doi.org/10.1182/blood.V120.21.2016.2016

Published: 2012

Journal Articles

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

John F. Seymour, MBBS FRACP, Michael Pfreundshuh, MD, B. Coiffier, MD, Marek Trneny, MD, PhD, Laurie H. Sehn, MD, Eva Csinady

Blood (2012) 120 (21): 58.

https://doi.org/10.1182/blood.V120.21.58.58

Published: 2012

Journal Articles

Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML

Adam Bryant, MD, Dawn Sheppard, MD, MSc, FRCPC, Christopher Bredeson, MD, MSc, FRCPC, Mitchell Sabloff, MDCM, FRCPC, MSc

Blood (2012) 120 (21): 2068.

https://doi.org/10.1182/blood.V120.21.2068.2068

Published: 2012

Journal Articles

Cardiovascular Risk: Analysis of Known Factors in Patients After Treosulfan-Based Conditioning for Haploidentical and HLA-Identical Stem Cell Transplantation

Alessandra Forcina, MD, Maria Teresa Lupo Stanghellini, MD, Raffaella Greco, MD, Alessandro Lorusso, MD, Daniela Clerici, MD, Jacopo Peccatori, Massimo Bernardi, MD, Francesca Lunghi, MD, Magda Marcatti, MD, Lionello Camba, MD, Elena Guggiari, MD, Andrea Assanelli, MD, Attilio Bondanza, MD, PhD, Matteo Carrabba, MD, Sarah Marktel, MD, Consuelo Corti, MD, Fabio Ciceri, MD

Blood (2011) 118 (21): 4471.

https://doi.org/10.1182/blood.V118.21.4471.4471

Published: 2011

Journal Articles

Successful Treatment of Acute Promyelocytic Leukemia (APL) In a Patient with Severe Cardiac Disease

Getinet D. Ayalew, MD, Michael I. Rotkowitz, MD, Juhi Mittal, MD, Gurinder Sidhu, MD, Albert S. Braverman, MD, Ratesh Khillan, MD

Blood (2010) 116 (21): 4369.

https://doi.org/10.1182/blood.V116.21.4369.4369

Published: 2010

Journal Articles

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Richard Aplenc, MD, MSCE, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1071.

https://doi.org/10.1182/blood.V116.21.1071.1071

Published: 2010

Journal Articles

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Richard A. Larson, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Gianantonio Rosti, MD, Jose L. Lopez, MD, Leif Stenke, MD, PhD, Hirohisa Nakamae, M.D., Ph.D., Stuart L. Goldberg, M.D., Ming-Chung Wang, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Christine-Elke Ortmann, Timothy P. Hughes, MD, MBBS, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 2291.

https://doi.org/10.1182/blood.V116.21.2291.2291

Published: 2010

Journal Articles

Pharmacokinetics of Nilotinib in Subjects with Normal or Impaired Hepatic Function.

Jaymes Holland, RPh, Chiaki Tanaka, PhD, Wei Zhou, PhD, Venkat Sethuraman, MS, Douglas M. Heuman, MD, Horst Schran

Blood (2007) 110 (11): 2379.

https://doi.org/10.1182/blood.V110.11.2379.2379

Published: 2007

Journal Articles

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

Marco Siano, M.D., Erika Lerch, M.D., Emanuele Zucca, M.D., Oreste Mora, M.D., Cristiana Sessa, M.D., Michele Ghielmini, MD

Blood (2007) 110 (11): 3411.

https://doi.org/10.1182/blood.V110.11.3411.3411

Published: 2007

Journal Articles

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

Miles Prince, MBBS, D.J. George, MD, R. Johnstone, PhD, C. McCormack, MBBS, L. Ellis, PhD, R. Williams-Truax, P. Atadja, PhD, C. Zhao, MD, M. Dugan, MD, K. Culver, MD

Blood (2006) 108 (11): 2715.

https://doi.org/10.1182/blood.V108.11.2715.2715

Published: 2006

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

Journal Articles

Survival in Individuals with Profound Anemia Treated without the Use of Blood Transfusions.

Patricia Ford, MD, Gina Keck, Jason Mastoris

Blood (2005) 106 (11): 949.

https://doi.org/10.1182/blood.V106.11.949.949

Published: 2005

NARROW

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML

Cardiovascular Risk: Analysis of Known Factors in Patients After Treosulfan-Based Conditioning for Haploidentical and HLA-Identical Stem Cell Transplantation

Successful Treatment of Acute Promyelocytic Leukemia (APL) In a Patient with Severe Cardiac Disease

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Pharmacokinetics of Nilotinib in Subjects with Normal or Impaired Hepatic Function.

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Survival in Individuals with Profound Anemia Treated without the Use of Blood Transfusions.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only